The exclusive requirement of PCa cells for AR activity is illuminated at clinic, wherein therapeutic suppression of AR signaling, typically achieved through ligand depletion and direct AR antagonists, results in PSA decline and objective tumor regressions. Here, KLK3 is linked to neoplasm.